Skip to content

Study · Observational study · n = 267 · 2024

7 results

REAL life study of subcutaneous SEMaglutide in patients with type 2 diabetes in SPain: Ambispective, multicenter clinical study. Results in the GLP1-experienced cohort.

Cárdenas-Salas JJ, Sierra Poyatos RM, Luca BL, Sánchez Lechuga B, Modroño Móstoles N, Montoya Álvarez T, Gómez Montes MP, Ruiz Sánchez JG, Meneses González D, Sánchez-Lopez R, Casado Cases C, Pérez de Arenaza Pozo V, Vázquez Martínez C

Journal of diabetes and its complications17 Sept 2024Cited by 2 (Europe PMC)

PMID39442257 (opens in a new tab)DOI10.1016/j.jdiacomp.2024.108874 (opens in a new tab)PepBankPUB-39442257
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes switched from another GLP-1 RA, once-weekly semaglutide was associated with a significant HbA1c reduction.

    In plain wordsIn adults with type 2 diabetes switched from another GLP-1 drug, semaglutide was linked to lower HbA1c.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change from baseline to 13 months
    Study

    n = 267

    Comparator
    Baseline before switch
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    HbA1c change
    −0.35%
    baseline to 13 months

    Source sentences

    Summary
    Switching to OW-semaglutide was associated with a significant reduction in HbA1c from baseline to 13 months (-0.35 % ± 0.81).
    2 context sentences
    Summary · context
    The primary outcome was the change in HbA1c at 12 ± 3 months of follow-up, with secondary outcomes including changes in weight, BMI, and other glycemic parameters.
    Summary · context
    Adult patients with T2DM who were prescribed once-weekly (OW) subcutaneous semaglutide and had been previously treated with other GLP-1 RAs were included.
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes switched to once-weekly semaglutide, body weight fell significantly.

    In plain wordsIn adults with type 2 diabetes switched to semaglutide, body weight went down.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight change
    Study

    n = 267

    Comparator
    Baseline before switch
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Significant reductions in weight
    2 context sentences
    Summary · context
    The primary outcome was the change in HbA1c at 12 ± 3 months of follow-up, with secondary outcomes including changes in weight, BMI, and other glycemic parameters.
    Summary · context
    Adult patients with T2DM who were prescribed once-weekly (OW) subcutaneous semaglutide and had been previously treated with other GLP-1 RAs were included.
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes switched to once-weekly semaglutide, BMI fell significantly.

    In plain wordsIn adults with type 2 diabetes switched to semaglutide, BMI went down.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI change
    Study

    n = 267

    Comparator
    Baseline before switch
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Significant reductions in weight, BMI
    2 context sentences
    Summary · context
    The primary outcome was the change in HbA1c at 12 ± 3 months of follow-up, with secondary outcomes including changes in weight, BMI, and other glycemic parameters.
    Summary · context
    Adult patients with T2DM who were prescribed once-weekly (OW) subcutaneous semaglutide and had been previously treated with other GLP-1 RAs were included.
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes switched to once-weekly semaglutide, fasting plasma glucose fell significantly.

    In plain wordsIn adults with type 2 diabetes switched to semaglutide, fasting blood sugar went down.

    Peptide
    Semaglutide
    Outcome
    DecreaseFasting plasma glucose change
    Study

    n = 267

    Comparator
    Baseline before switch
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Significant reductions in weight, BMI, and fasting plasma glucose were also observed.
    1 context sentence
    Summary · context
    Adult patients with T2DM who were prescribed once-weekly (OW) subcutaneous semaglutide and had been previously treated with other GLP-1 RAs were included.
  5. 05HumanObservational studySafety outcome

    In adults with type 2 diabetes switched to once-weekly semaglutide, adverse events were mostly gastrointestinal.

    In plain wordsIn adults with type 2 diabetes switched to semaglutide, most side effects affected the digestive system.

    Peptide
    Semaglutide
    Outcome
    Not applicableGastrointestinal adverse events
    Study

    n = 267

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Adverse events were mostly gastrointestinal
    1 context sentence
    Summary · context
    Adult patients with T2DM who were prescribed once-weekly (OW) subcutaneous semaglutide and had been previously treated with other GLP-1 RAs were included.
  6. 06HumanObservational studySafety outcome

    In adults with type 2 diabetes switched to once-weekly semaglutide, adverse events led to treatment withdrawal in few cases.

    In plain wordsIn adults with type 2 diabetes switched to semaglutide, few people stopped treatment because of side effects.

    Peptide
    Semaglutide
    Outcome
    Not applicableTreatment withdrawal due to adverse events
    Study

    n = 267

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Adverse events were mostly gastrointestinal and led to treatment withdrawal in few cases.
    1 context sentence
    Summary · context
    Adult patients with T2DM who were prescribed once-weekly (OW) subcutaneous semaglutide and had been previously treated with other GLP-1 RAs were included.
  7. 07HumanObservational studyEfficacy outcome

    Patients who reached 1.0 mg once weekly had a significantly larger HbA1c reduction than patients on 0.5 mg or less.

    In plain wordsIn adults with type 2 diabetes, the 1.0 mg weekly semaglutide dose gave a bigger HbA1c drop than 0.5 mg or less.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c by semaglutide dose
    Study

    n: not reported in source

    Comparator
    Dose of 0.5 mg or less once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.0 mg once weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Patients who reached the 1.0 mg OW-dose showed a significant reduction in HbA1c compared to those on the ≤0.5 mg OW-dose.
    1 context sentence
    Summary · context
    Adult patients with T2DM who were prescribed once-weekly (OW) subcutaneous semaglutide and had been previously treated with other GLP-1 RAs were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.